Lates News

Johnson & Johnson's Akeega received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, used for the treatment of metastatic hormone-sensitive prostate cancer patients carrying BRCA1/2 gene mutations.